Cited by 5,161Opioid Use Disorder TreatmentPain Management and Opioid UseAnesthesia and Pain Management

CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016

Open access
Dowell, Deborah, Haegerich, Tamara M., Chou, Roger·2016·JAMA

Abstract

IMPORTANCE: Primary care clinicians find managing chronic pain challenging. Evidence of long-term efficacy of opioids for chronic pain is limited. Opioid use is associated with serious risks, including opioid use disorder and overdose. OBJECTIVE: To provide recommendations about opioid prescribing for primary care clinicians treating adult patients with chronic pain outside of active cancer treatment, palliative care, and end-of-life care. PROCESS: The Centers for Disease Control and Prevention (CDC) updated a 2014 systematic review on effectiveness and risks of opioids and conducted a supplemental review on benefits and harms, values and preferences, and costs. CDC used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework to assess evidence type and determine the recommendation category. EVIDENCE SYNTHESIS: Evidence consisted of observational studies or randomized clinical trials with notable limitations, characterized as low quality using GRADE methodology. Meta-analysis was not attempted due to the limited number of studies, variability in study designs and clinical heterogeneity, and methodological shortcomings of studies. No study evaluated long-term (≥1 year) benefit of opioids for chronic pain. Opioids were associated with increased risks, including opioid use disorder, overdose, and death, with dose-dependent effects. RECOMMENDATIONS: There are 12 recommendations. Of primary importance, nonopioid therapy is preferred for treatment of chronic pain. Opioids should be used only when benefits for pain and function are expected to outweigh risks. Before starting opioids, clinicians should establish treatment goals with patients and consider how opioids will be discontinued if benefits do not outweigh risks. When opioids are used, clinicians should prescribe the lowest effective dosage, carefully reassess benefits and risks when considering increasing dosage to 50 morphine milligram equivalents or more per day, and avoid concurrent opioids and benzodiazepines whenever possible. Clinicians should evaluate benefits and harms of continued opioid therapy with patients every 3 months or more frequently and review prescription drug monitoring program data, when available, for high-risk combinations or dosages. For patients with opioid use disorder, clinicians should offer or arrange evidence-based treatment, such as medication-assisted treatment with buprenorphine or methadone. CONCLUSIONS AND RELEVANCE: The guideline is intended to improve communication about benefits and risks of opioids for chronic pain, improve safety and effectiveness of pain treatment, and reduce risks associated with long-term opioid therapy.

Integrity signals

Registry

Crossref · 10.1001/jama.2016.1464

Cites

214 of 214 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

0 of 23 cited sources checked · 0 supported · 0 flagged

  • Finding

    The guideline says nonopioid therapy is preferred for chronic pain and opioids should be used only when expected benefits outweigh risks.

    “Of primary importance, nonopioid therapy is preferred for treatment of chronic pain. Opioids should be used only when benefits for pain and function are expected to outweigh risks.”
    Quote in the paperNot yet classified
  • Finding

    When opioids are used, clinicians should prescribe the lowest effective dosage and carefully reassess benefits and risks when considering doses of 50 morphine milligram equivalents or more per day.

    “When opioids are used, clinicians should prescribe the lowest effective dosage, carefully reassess benefits and risks when considering increasing dosage to 50 morphine milligram equivalents or more per day,”
    Quote in the paperNot yet classified
  • Finding

    Nonpharmacologic and nonopioid pharmacologic treatments were found to be effective for chronic pain in studies lasting 2 weeks to 6 months.

    “Several nonpharmacologic and nonopioid pharmacologic treatments were found to be effective for chronic pain in studies ranging in duration from 2 weeks to 6 months48–66 (Table 3).”
    Quote in the paperNot yet classified0 of 10 sources checked
    • cites [48]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [49]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [50]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [51]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [52]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [53]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [54]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [55]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [56]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites [57]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Finding

    No study evaluated long-term benefit of opioids for chronic pain.

    “No study evaluated long-term (≥1 year) benefit of opioids for chronic pain.”
    Quote in the paperNot yet classified
  • Finding

    The recommendations are voluntary rather than prescriptive standards and are based on emerging evidence with notable limitations.

    “The recommendations in the guideline are voluntary, rather than prescriptive standards. They are based on emerging evidence, including observational studies or randomized clinical trials with notable limitations.”
    Quote in the paperNot yet classified

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • More than a quarter of patients in a study of almost 100,000 were tapering at a rate faster than 40% of their original dose per month, even higher than the maximum rate recommended by the CDC.

    “A study of almost 100,000 patients found that the average rate of tapering was 34.0% of the original dose per month and more than a quarter of patients were tapering at a rate faster than 40% of their original dose per month,43,49 even higher than the maximum rate recommended by the CDC. 1”

    From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [1]

    The Recommendations section describes a decrease of 10% of the original dose per week as a reasonable starting point, not a maximum rate. It also says tapering plans may be individualized and more rapid tapers might be needed after an overdose. The study's patient counts and tapering rates are attributed to other citations in the citing sentence, not to this CDC guideline. (LLM, conf=0.89)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured
  • Opioids are significantly less effective against chronic pain (neuropathic pain, fibromyalgia, low-back pain) and tolerance develops to their analgesic effects, necessitating higher doses.

    “However, opioids are significantly less effective against chronic pain, such as neuropathic pain, fibromyalgia, and low-back pain, and tolerance develops to the analgesic effects of opioids, thus necessitating the need for increasingly higher doses to sustain analgesia (McQuay, 1988;Dowell et al., 2016).”

    From Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development (2021) · cites this paper as Dowell et al., 2016

    The Clinical Evidence Review (page not provided) says opioids provide moderate short-term pain relief and that tolerance can diminish response over time, while long-term benefit for chronic pain remains uncertain. It does not establish that opioids are significantly less effective for the three named conditions or that tolerance necessitates increasingly higher doses; the Recommendations instead advise reassessment when dose requirements escalate. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • The CDC Guideline for Prescribing Opioids recommends a linear reduction of opioid doses: a decrease of 10% of the original dose per week or slower tapers such as 10% per month for longer term users.

    “The influential Centres for Disease Control (CDC) Guideline for Prescribing Opioids recommends a linear reduction of opioid doses: ‘A decrease of 10% of the original dose per week’ or ‘slower tapers (e.g. 10% per month)’ for longer term users (Figure 1(a)). 1”
  • Opioids are associated with substantial systemic harm such as worsening psychopathology, addiction, tolerance, and premature death.

    “Opioids are also associated with substantial systemic harm such as worsening psychopathology, addiction, tolerance, and premature death. 24”
  • The Centers for Disease Control and Prevention and FDA issued warnings in 2016 to make prescribers and patients aware of risks of combining benzodiazepines with other CNS depressants.

    “The Centers for Disease Control and Prevention and US Food and Drug Administration issued warnings in 2016 to make prescribers and patients aware of these risks.19,34”

Cites

Flagged first, then by citations

1 of the 215 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Dowell, D., Haegerich, T. M., & Chou, R.
Affiliations
Centers for Disease Control and Prevention (US)
Corresponding author
Dowell, Deborah
Venue
JAMA
Published
2016-04-19
Volume
315
Issue
15
Pages
1624
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2296986887
Cited by
5,161
References
215
Citations by year
2026: 137 · 2025: 233 · 2024: 272 · 2023: 347 · 2022: 407 · 2021: 733 · 2020: 825 · 2019: 762 · 2018: 701 · 2017: 525 · 2016: 214 · 2015: 1 · 2014: 1
FWCI
723.61
Type
journal article
Language
en
Open access
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (CC999999)
  • Agency for Healthcare Research and Quality
  • U.S. Public Health Service (200-2013-M-53890, 15IPA-1505478, 290201200014I)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
  • Health Sciences › Medicine › Surgery › Anesthesia and Pain Management
Keywords
opioid prescribing, chronic pain, opioid use disorder, opioid overdose, benzodiazepines, prescription drug monitoring programs, buprenorphine, methadone, medication-assisted treatment, low-dose opioids, primary care
MeSH terms
Contraindications, Adult, Analgesics, Opioid, Benzodiazepines, Centers for Disease Control and Prevention, U.S., Communication, Drug Therapy, Combination, Goals, Humans, Drug Prescriptions, Primary Health Care, United States, Randomized Controlled Trials as Topic, Treatment Outcome, Withholding Treatment, Chronic Pain, Acute Pain, Prescription Drug Misuse, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read (extract-v1) on 2026-09-24.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review